Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.

about

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.

Item

http://www.wikidata.org/entity/Q48585692

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@en

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@nl

type

Item

label

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@en

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@nl

prefLabel

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@en

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@nl

P1476

Incorporating BEAMing technolo ...... s: an expert taskforce review.

@en

P2093

A Vivancos

http://www.w3.org/2001/XMLSchema#string

E Alba

http://www.w3.org/2001/XMLSchema#string

E Aranda

http://www.w3.org/2001/XMLSchema#string

E Díaz-Rubio

http://www.w3.org/2001/XMLSchema#string

J García-Foncillas

http://www.w3.org/2001/XMLSchema#string

R López-López

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Circulating mutant DNA to assess tumor dynamics

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Detection of circulating tumor DNA in early- and late-stage human malignancies

Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients.

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.

Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

P304

2943-2949

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1093/ANNONC/MDX501

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P5008

ScienceSource

P577

2017-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28945877

http://www.w3.org/2001/XMLSchema#string

P921

biopsy

colorectal cancer

colorectal neoplasm

biomedical investigative technique

DNA

P932

5834030

http://www.w3.org/2001/XMLSchema#string